Effect of cyclooxygenase inhibitors in a xenograft model of canine mammary tumours

Veterinary and Comparative Oncology

Volumn 9, Issue 3, 2011, Pages 161-171

  Sonzogni Desautels, K ^a   Knapp, D W ^b   Sartin, E ^c   Dore M ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b PURDUE UNIVERSITY   (United States)

^c AUBURN UNIVERSITY   (United States)

Author keywords

COX 2; Deracoxib; Dogs; Mammary cancer; Piroxicam; Prostaglandins

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DERACOXIB; PIROXICAM; PROSTAGLANDIN SYNTHASE INHIBITOR; SULFONAMIDE;

ANIMAL; ARTICLE; DISEASE MODEL; DOG; DOG DISEASE; DRUG SCREENING; EXPERIMENTAL NEOPLASM; FEMALE; MOUSE; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; DOG DISEASES; DOGS; FEMALE; MAMMARY NEOPLASMS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; PIROXICAM; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

CANIS FAMILIARIS; MURINAE; MUS; MUS MUSCULUS;

EID: 80051739063     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2010.00242.x     Document Type: Article

References (63)

1. Levy GN. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. The FASEB Journal 1997; 11: 234-247.
2. Miyamoto T, Ogino N, Yamamoto S and Hayaishi O. Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. The Journal of Biological Chemistry 1976; 251: 2629-2636.
3. Simmons DL, Levy DB, Yannoni Y and Erikson RL. Identification of a phorbol ester-repressible v-src-inducible gene. Proceedings of the National Academy of Sciences of the United States of America 1989; 86: 1178-1182.
4. Howe LR, Subbaramaiah K, Brown AM and Dannenberg AJ. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocrine-Related Cancer 2001; 8: 97-114.
5. Kam PC and See AU. Cyclo-oxygenase isoenzymes: physiological and pharmacological role. Anaesthesia 2000; 55: 442-449.
6. Vane JR, Bakhle YS and Botting RM. Cyclooxygenases 1 and 2. Annual Review of Pharmacology and Toxicology 1998; 38: 97-120.
7. Fitzpatrick FA and Soberman R. Regulated formation of eicosanoids. The Journal of Clinical Investigation 2001; 107: 1347-1351.
8. Doré M, Lanthier I and Sirois J. Cyclooxygenase-2 expression in canine mammary tumors. Veterinary Pathology 2003; 40: 207-212.
9. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J and Koki AT. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000; 89: 2637-2645.
10. Pestili de Almeida EM, Piche C, Sirois J and Dore M. Expression of cyclo-oxygenase-2 in naturally occurring squamous cell carcinomas in dogs. The Journal of Histochemistry and Cytochemistry 2001; 49: 867-875.
11. Mutsaers AJ, Mohammed SI, DeNicola DB, Snyder PW, Glickman NW, Bennett PF, de Gortari AE, Bonney PL and Knapp DW. Pretreatment tumor prostaglandin E2 concentration and cyclooxygenase-2 expression are not associated with the response of canine naturally occurring invasive urinary bladder cancer to cyclooxygenase inhibitor therapy. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2005; 72: 181-186.
12. Khan KN, Knapp DW, Denicola DB and Harris RK. Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs. American Journal of Veterinary Research 2000; 61: 478-481.
13. Khan KN, Stanfield KM, Trajkovic D and Knapp DW. Expression of cyclooxygenase-2 in canine renal cell carcinoma. Veterinary Pathology 2001; 38: 116-119.
14. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S and DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-1188.
15. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M and Hla T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Research 1995; 55: 3785-3789.
16. Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ and Murray FE. The relationship between cyclooxygenase-2 expression and colorectal cancer. Journal of the American Medical Association 1999; 282: 1254-1257.
17. Boland GP, Butt IS, Prasad R, Knox WF and Bundred NJ. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. British Journal of Cancer 2004; 90: 423-429.
18. Half E, Tang XM, Gwyn K, Sahin A, Wathen K and Sinicrope FA. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Research 2002; 62: 1676-1681.
19. Denkert C, Winzer KJ, Muller BM, Weichert W, Pest S, Kobel M, Kristiansen G, Reles A, Siegert A, Guski H and Hauptmann S. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 2003; 97: 2978-2987.
20. Millanta F, Citi S, Della Santa D, Porciani M and Poli A. COX-2 expression in canine and feline invasive mammary carcinomas: correlation with clinicopathological features and prognostic molecular markers. Breast Cancer Research and Treatment 2006; 98: 115-120.
21. Queiroga FL, Alves A, Pires I and Lopes C. Expression of Cox-1 and Cox-2 in canine mammary tumours. Journal of Comparative Pathology 2007; 136: 177-185.
22. Lavalle GE, Bertagnolli AC, Tavares WLF and Cassali GD. Cox-2 expression in canine mammary carcinomas: correlation with angiogenesis and overall survival. Veterinary Pathology 2009; 46: 1275-1280.
23. Howe LR and Dannenberg AJ. COX-2 inhibitors for the prevention of breast cancer. Journal of Mammary Gland Biology and Neoplasia 2003; 8: 31-43.
24. Seno H, Oshima M, Ishikawa TO, Oshima H, Takaku K, Chiba T, Narumiya S and Taketo MM. Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Research 2002; 62: 506-511.
25. Sheng H, Shao J, Morrow JD, Beauchamp RD and DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Research 1998; 58: 362-366.
26. Tsujii M, Kawano S and DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proceedings of the National Academy of Sciences of the United States of America 1997; 94: 3336-3340.
27. Thun MJ, Namboodiri MM and Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. New England Journal of Medicine 1991; 325: 1593-1596.
28. Schreinemachers DM and Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994; 5: 138-146.
29. Jacobs EJ, Thun MJ, Connell CJ, Rodriguez C, Henley SJ, Feigelson HS, Patel AV, Flanders WD and Calle EE. Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort. Cancer Epidemiology, Biomarkers & Prevention 2005; 14: 261-264.
30. Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL, Britton JA, Subbaramaiah K, Dannenberg AJ and Neugut AI. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. Journal of the American Medical Association 2004; 291: 2433-2440.
31. García Rodríguez LA and Gonzalez-Perez A. Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. British Journal of Cancer 2004; 91: 525-529.
32. Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, Loar A, Rodabough RJ, White E and McTiernan A. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Research 2003; 63: 6096-6101.
33. Johnson TW, Anderson KE, Lazovich D and Folsom AR. Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiology, Biomarkers & Prevention 2002; 11: 1586-1591.
34. Merlo DF, Rossi L, Pellegrino C, Ceppi M, Cardellino U, Capurro C, Ratto A, Sambucco PL, Sestito V, Tanara G and Bocchini V. Cancer incidence in pet dogs: findings of the Animal Tumor Registry of Genoa, Italy. Journal of Veterinary Internal Medicine 2008; 22: 976-984.
35. Schneider R, Dorn CR and Taylor DO. Factors influencing canine mammary cancer development and postsurgical survival. Journal of the National Cancer Institute 1969; 43: 1249-1261.
36. Boldizsár H, Muray T, Szamel I, Szenci O and Csenki J. Studies on canine mammary tumours. II. Oestradiol and progesterone receptor binding capacity and histological type. Acta Veterinaria Hungarica 1992; 40: 89-97.
37. Ogilvie GK, Reynolds HA, Richardson RC, Withrow SJ, Norris AM, Henderson RA, Klausner JS, Fowler JD and McCaw D. Phase II evaluation of doxorubicin for treatment of various canine neoplasms. Journal of the American Veterinary Medical Association 1989; 195: 1580-1583.
38. Knapp DW, Richardson RC, Bottoms GD, Teclaw Rand Chan TC. Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemotherapy and Pharmacology 1992; 29: 214-218.
39. Knottenbelt C, Chambers G, Gault E and Argyle DJ. The in vitro effects of piroxicam and meloxicam on canine cell lines. Journal of Small Animal Practice 2006; 47: 14-20.
40. Brunelle M, Sartin EA, Wolfe LG, Sirois J and Dore M. Cyclooxygenase-2 expression in normal and neoplastic canine mammary cell lines. Veterinary Pathology 2006; 43: 656-666.
41. Wolfe LG, Smith BB, Toivio-Kinnucan MA, Sartin EA, Kwapien RP, Henderson RA and Barnes S. Biologic properties of cell lines derived from canine mammary carcinomas. Journal of the National Cancer Institute 1986; 77: 783-792.
42. Mohammed SI, Dhawan D, Abraham S, Snyder PW, Waters DJ, Craig BA, Lu M, Wu L, Zheng R, Stewart J and Knapp DW. Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects. Molecular Cancer Therapeutics 2006; 5: 329-336.
43. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA and Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Research 1995; 55: 2556-2559.
44. Price JE, Polyzos A, Zhang RD and Daniels LM. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Research 1990; 50: 717-721.
45. Kune GA, Kune S and Watson LF. Colorectal cancer risk, chronic illnesses, operations and medications: case control results from the Melbourne Colorectal Cancer Study. 1988. International Journal of Epidemiology 2007; 36: 951-957.
46. Gierach GL, Lacey JV Jr, Schatzkin A, Leitzmann MF, Richesson D, Hollenbeck AR and Brinton LA. Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Research 2008; 10: R38.
47. Harris RE, Alshafie GA, Abou-Issa H and Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Research 2000; 60: 2101-2103.
48. Barnes NL, Warnberg F, Farnie G, White D, Jiang W, Anderson E and Bundred NJ. Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. British Journal of Cancer 2007; 96: 575-582.
49. Connolly EM, Harmey JH, O'Grady T, Foley D, Roche-Nagle G, Kay E and Bouchier-Hayes DJ. Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer. British Journal of Cancer 2002; 87: 231-237.
50. Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, Thaler HT, Muller WJ, Du B, Brown AM and Dannenberg AJ. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Research 2002; 62: 5405-5407.
51. Schiffmann S, Maier TJ, Wobst I, Janssen A, Corban-Wilhelm H, Angioni C, Geisslinger G and Grösch S. The anti-proliferative potency of celecoxib is not a class effect of coxibs. Biochemical Pharmacology 2008; 76: 179-187.
52. Mohammed SI, Bennett PF, Craig BA, Glickman NW, Mutsaers AJ, Snyder PW, Widmer WR, DeGortari AE, Bonney PL and Knapp DW. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Research 2002; 62: 356-358.
53. Schmidt BR, Glickman NW, DeNicola DB, de Gortari AE and Knapp DW. Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs. Journal of the American Veterinary Medical Association 2001; 218: 1783-1786.
54. Sorenmo KU, Goldschmidt MH, Shofer FS, Goldkamp C and Ferracone J. Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma. Veterinary and Comparative Oncology 2004; 2: 13-23.
55. Galbraith EA and McKellar QA. Pharmacokinetics and pharmacodynamics of piroxicam in dogs. Veterinary Record 1991; 128: 561-565.
56. Schiantarelli P, Acerbi D and Bovis G. Some pharmacokinetic properties and bioavailability by oral and rectal route of piroxicam in rodents and in man. Arzneimmittel-Forschung/Drug Research 1981; 31: 92-97.
57. Streppa HK, Jones CJ and Budsberg SC. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs in canine blood. American Journal of Veterinary Research 2002; 63: 91-94.
58. Cryer B and Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. American Journal of Medicine 1998; 104: 413-421.
59. Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, Sessoms A, Dunson DB, Rogan EG, Morham SG, Smart RC and Langenbach R. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Research 2002; 62: 3395-3401.
60. Gupta RA, Tejada LV, Tong BJ, Das SK, Morrow JD, Dey SK and DuBois RN. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Research 2003; 63: 906-911.
61. Daikoku T, Wang D, Tranguch S, Morrow JD, Orsulic S, DuBois RN and Dey SK. Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Research 2005; 65: 3735-3744.
62. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC and Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. Journal of the American Medical Association 2005; 294: 914-923.
63. Matsumoto G, Rahman MA, Muta M, Nakamura T, Bando H, Saji S, Tsuruta K, Okamoto A and Toi M. DFU, a selective COX-2 inhibitor, suppresses MCF-7 xenograft tumor growth in mice. Oncology Reports 2004; 12: 281-285.